

## Modélisation, Epidémiologie et Surveillance des risques sanitaires

### Publications de 2016

#### Articles scientifiques

Jean K, Donnelly CA, Ferguson NM, Garske T. [A Meta-Analysis of Serological Response Associated with Yellow Fever Vaccination](#). *Am J Trop Med Hyg*. 2016 Dec 7 ;95(6):1435-1439.

Jean K, Boily MC, Danel C, Moh R, Badjé A, Desgrées-du-Loû A, Eholié S, Lert F, Dray-Spira R, Anglaret X, Ouattara E. [What Level of Risk Compensation Would Offset the Preventive Effect of Early Antiretroviral Therapy ? Simulations From the TEMPRANO Trial](#). *Am J Epidemiol*. 2016 Nov 15 ;184(10):755-760.

Nedellec V, Rabl A. [Costs of Health Damage from Atmospheric Emissions of Toxic Metals : Part 2-Analysis for Mercury and Lead](#). *Risk Anal*. 2016 Nov ;36(11):2096-2104.

Nedellec V, Rabl A. [Costs of Health Damage from Atmospheric Emissions of Toxic Metals : Part 1-Methods and Results](#). *Risk Anal*. 2016 Nov ;36(11):2081-2095.

Assab R, Temime L. [The role of hand hygiene in controlling norovirus spread in nursing homes](#). *BMC Infect Dis*. 2016 Aug 9 ;16:395.

Nedellec V, Rabl A, Dab W. [Public health and chronic low chlordcone exposures in Guadeloupe ; Part 2 : Health impacts, and benefits of prevention](#). *Environ Health*. 2016 Jul 19 ;15(1):78.

Nedellec V, Rabl A, Dab W. [Public health and chronic low chlordcone exposure in Guadeloupe, Part 1 : hazards, exposure-response functions, and exposures](#). *Environ Health*. 2016 Jul 12 ;15(1):75.

Hocine MN, Aït Bouziad K, Légeron P, Dab W, Saporta G. [How to Identify and Prioritize Psychosocial Factors Impacting Stress Level](#). *PLoS One*. 2016 Jun 15 ;11(6):e0157078.

#### Communications dans des conférences internationales

## **American Society of Tropical Medicine and Hygiene - 65th Annual Meeting**

**Jean K**, Ferguson NM, Van Kerkhove MD, Yactayo S, Perea W, Biey J, Shibeshi ME, Garske T. The differential impact of Yellow Fever vaccine across transmission cycles: accounting for herd immunity in the face of zoonotic transmission. **65th Annual Meeting American Society of Tropical Medicine and Hygiene (ASTMH)**. November 13-17, 2016. Atlanta, USA. Poster

## **30th Annual North American Cystic Fibrosis Conference**

**Nkam L**, Lambert J, Latouche A, Bellis G, Burgel PR, Hocine MN. Dynamic prediction of death or lung transplantation for patients with cysticfibrosis using joint model for longitudinal and time-to-event data . **30th annual North American Cystic Fibrosis Conference - NACFC**. October 27-29, 2016. Orlando, Florida, États-Unis. Poster

## **39th European Cystic Fibrosis Society Conference**

**Nkam L**, Lambert J, Latouche A, Bellis G, Burgel PR, Hocine MN. A 3-year predictive model of French patients with cystic fibrosis. **ECFS2016 - 39th European Cystic Fibrosis SocietyConference**. June 8-11, 2016. Basel, Switzerland . Oral. **Young Investigator Award**.

## **8ème Conférence Internationale Francophone de lutte contre le VIH et les hépatites**

**Jean K**, Niangoran S, Danel C, Moh R, Gabillard D, Ouattara E, Eholié S, Lert F, Anglaret X, Dray-Spira R, Desgrées-du-Loû A. Les conséquences sociales et comportementales de l'initiation précoce du traitement ARV en Afrique : l'étude TEMPRANO Social (Abidjan, Côte d'Ivoire, ANRS 12239). **AFRAVIH - 8ème Conf. Francophone VIH/SIDA**. April 20-23, 2016. Bruxelles, Belgium. Oral

## **26th European Congress of Clinical Microbiology and Infectious Diseases**

**Nekkab N**, Crépey P, Astagneau P. Modelling the spread of hospital-acquired infections in France : a comparison of patient transfer networks. **ECCMID 2016 - 26th European Congress of Clinical Microbiology and Infectious Diseases**. April 9-12, 2016. Amsterdam, The Netherlands. Poster

## **Colloque Français et Européen des Jeunes Chercheurs de Mucoviscidose**

**Nkam**. et al., Prédition de la survie à 5 ans des patients atteints de mucoviscidose en France. **Colloque Français et Européen des Jeunes Chercheurs de Mucoviscidose**. February 9-12, 2016. Paris, France. Oral

## Conférences invitées

Dab W. Prévention dans les branches et les entreprises : quels bénéfices ? **Université de la protection sociale.** Sept 2016, Brussels, Belgium.

Jean K. *Modélisation de la fièvre jaune et impact des stratégies vaccinales en Afrique.* **Séminaires Recherche et Pratique en Santé Publique, ISPED-Inserm 1219.** Bordeaux, France.

Jean K. *Social and behavioural consequences of early ART initiation in West Africa: the TEMPRANO SOCIAL study (Abidjan, Côte d'Ivoire, ANRS 12239).* **London School of Hygiene and Tropical Medicine.** London, UK.

<https://mesurs.cnam.fr/publications/articles/publications-de-2016-1255705.kjsp?RH=1650614504542>